Target Interacting Protein Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T12355 | Target Info | |||
Target Name | G1/S-specific cyclin-D1 (CCND1) | ||||
Synonyms | PRAD1 oncogene; PRAD1; Cyclin D1; BCL1; BCL-1 oncogene; BCL-1; B-cell lymphoma 1 protein | ||||
Target Type | Clinical trial Target | ||||
Gene Name | CCND1 | ||||
UniProt ID |
Target Interacting Proteins | Top | ||||
---|---|---|---|---|---|
Acyltransferases | [+] 2 Acyltransferases | + | |||
Interacting Target Name | Histone acetyltransferase p300 (EP300) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Protein propionyltransferase p300; p300 HAT; P300; Histone crotonyltransferase p300; Histone butyryltransferase p300; E1A-associated protein p300; E1Aassociated protein p300 | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [1] | |||
2 | Reconstituted Complex | [2] | |||
Interacting Protein Name | Transcription initiation factor TFIID subunit 1 (TAF1) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | BA2R; CCG1; CCGS; DYT3; DYT3/TAF1; KAT4; N.TAF1; NSCL2; OF; P250; TAF(II)250; TAF2A; TAFII.250; TAFII250; XDP | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [3] | |||
2 | Reconstituted Complex | [4] | |||
Carbon-nitrogen hydrolases | [+] 2 Carbon-nitrogen hydrolases | + | |||
Interacting Target Name | Histone deacetylase 3 (HDAC3) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | SMAP45; RPD3-2; RPD32; HD3 | ||||
Evidence Score (E-score) | 4 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [5] | |||
2 | Affinity Capture-Western | [6] | |||
3 | Affinity Capture-Western | [7] | |||
4 | Co-localization | [8] | |||
Interacting Target Name | Histone deacetylase 1 (HDAC1) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | RPD3L1; HD1 | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [6] | |||
2 | Co-localization | [8] | |||
Cell cycle related proteins | [+] 1 Cell cycle related proteins | + | |||
Interacting Target Name | Multiple tumor suppressor 1 (CDKN2A) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Tumour suppressor gene p16; P16-INK4a; p16INK4A; P16-INK4; P16 gene; MTS-1; Cyclin-dependent kinase inhibitor 2A; Cyclin-dependent kinase 4 inhibitor A; CDK4I | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [9] | |||
2 | Co-fractionation | [10] | |||
Cell division cycle proteins | [+] 1 Cell division cycle proteins | + | |||
Interacting Protein Name | Retinoblastoma-associated protein (RB1) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | OSRC; PPP1R130; RB; p105.Rb; pRb; pp110 | ||||
Evidence Score (E-score) | 15 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [11] | |||
2 | Biochemical Activity | [12] | |||
3 | Biochemical Activity | [13] | |||
4 | Biochemical Activity | [14] | |||
5 | Biochemical Activity | [15] | |||
6 | Biochemical Activity | [16] | |||
7 | Biochemical Activity | [11] | |||
8 | Biochemical Activity | [17] | |||
9 | Biochemical Activity | [18] | |||
10 | Biochemical Activity | [19] | |||
11 | Biochemical Activity | [20] | |||
12 | Biochemical Activity | [21] | |||
13 | Biochemical Activity | [22] | |||
14 | Reconstituted Complex | [4] | |||
15 | Reconstituted Complex | [23] | |||
Kinases | [+] 4 Kinases | + | |||
Interacting Target Name | Cyclin-dependent kinase 4 (CDK4) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | PSK-J3; Cell division protein kinase 4 | ||||
Evidence Score (E-score) | 20 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [24] | |||
2 | Affinity Capture-MS | [25] | |||
3 | Affinity Capture-Western | [26] | |||
4 | Affinity Capture-Western | [13] | |||
5 | Affinity Capture-Western | [15] | |||
6 | Affinity Capture-Western | [27] | |||
7 | Affinity Capture-Western | [28] | |||
8 | Affinity Capture-Western | [29] | |||
9 | Affinity Capture-Western | [30] | |||
10 | Affinity Capture-Western | [31] | |||
11 | Affinity Capture-Western | [32] | |||
12 | Affinity Capture-Western | [33] | |||
13 | Affinity Capture-Western | [34] | |||
14 | Affinity Capture-Western | [35] | |||
15 | Affinity Capture-Western | [36] | |||
16 | Affinity Capture-Western | [37] | |||
17 | Co-fractionation | [38] | |||
18 | Co-fractionation | [10] | |||
19 | Reconstituted Complex | [39] | |||
20 | Reconstituted Complex | [35] | |||
Interacting Target Name | Cyclin-dependent kinase 6 (CDK6) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Serine/threonine-protein kinase PLSTIRE; Serine/threonine protein kinase PLSTIRE; Cell division protein kinase 6; CDKN6 | ||||
Evidence Score (E-score) | 4 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [15] | |||
2 | Affinity Capture-Western | [36] | |||
3 | Co-fractionation | [10] | |||
4 | Reconstituted Complex | [39] | |||
Interacting Target Name | Cyclin-dependent kinase 1 (CDK1) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | P34CDC2; P34 protein kinase; CDKN1; CDC28A; CDC2 | ||||
Evidence Score (E-score) | 3 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [24] | |||
2 | Affinity Capture-MS | [9] | |||
3 | Affinity Capture-Western | [40] | |||
Interacting Target Name | Cyclin-dependent kinase 2 (CDK2) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | SIN3-associated protein; Sin3 associated polypeptide; P33 protein kinase; Cell division protein kinase 2; CDKN2 | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [24] | |||
2 | Affinity Capture-Western | [15] | |||
Nuclear hormone receptors | [+] 2 Nuclear hormone receptors | + | |||
Interacting Target Name | Estrogen receptor (ESR) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Oestrogen receptor alpha; Oestrogen receptor; Nuclear receptor subfamily 3 group A member 1; NR3A1; Estrogen receptor alpha; Estradiol receptor; ESR; ER-alpha; ERalpha; ER | ||||
Evidence Score (E-score) | 3 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [41] | |||
2 | Reconstituted Complex | [42] | |||
3 | Yeast two hybrid | [42] | |||
Interacting Target Name | Androgen receptor (AR) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Testosterone receptor; Nuclear receptor subfamily 3 group C member 4; NR3C4; Dihydrotestosterone receptor; DHTR; Androgen receptor | ||||
Evidence Score (E-score) | 3 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [5] | |||
2 | Affinity Capture-Western | [43] | |||
3 | Reconstituted Complex | [5] | |||
Other proteins | [+] 5 Other proteins | + | |||
Interacting Target Name | Melanoma differentiation-associated protein 6 (CDKN1A) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | WAF1; SDI1; PIC1; P21(WAF1); P21; Melanoma differentiation associated protein 6; MDA-6; MDA6; Cyclin-dependent kinase inhibitor 1; CIP1; CDK-interacting protein 1; CAP20 | ||||
Evidence Score (E-score) | 13 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [24] | |||
2 | Affinity Capture-Western | [44] | |||
3 | Affinity Capture-Western | [34] | |||
4 | Affinity Capture-Western | [35] | |||
5 | Affinity Capture-Western | [45] | |||
6 | Affinity Capture-Western | [16] | |||
7 | Co-fractionation | [10] | |||
8 | Reconstituted Complex | [46] | |||
9 | Reconstituted Complex | [47] | |||
10 | Reconstituted Complex | [35] | |||
11 | Reconstituted Complex | [39] | |||
12 | Yeast two hybrid | [48] | |||
13 | Yeast two hybrid | [49] | |||
Interacting Target Name | CDK inhibitor 1B p27Kip1 (CDKN1B) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | p27Kip1; KIP1; Cyclin-dependent kinase inhibitor p27; Cyclindependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor 1B | ||||
Evidence Score (E-score) | 10 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [24] | |||
2 | Affinity Capture-MS | [9] | |||
3 | Affinity Capture-Western | [50] | |||
4 | Affinity Capture-Western | [31] | |||
5 | Affinity Capture-Western | [32] | |||
6 | Affinity Capture-Western | [33] | |||
7 | Affinity Capture-Western | [45] | |||
8 | Affinity Capture-Western | [51] | |||
9 | Reconstituted Complex | [52] | |||
10 | Yeast two hybrid | [48] | |||
Interacting Protein Name | F-box only protein 4 (FBXO4) | Interacting Protein | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | FBX4 | ||||
Evidence Score (E-score) | 4 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [53] | |||
2 | Affinity Capture-Western | [26] | |||
3 | Affinity Capture-Western | [54] | |||
4 | Reconstituted Complex | [53] | |||
Interacting Target Name | Proliferating cell nuclear antigen (PCNA) | Clinical trial Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Cyclin | ||||
Evidence Score (E-score) | 3 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [55] | |||
2 | Affinity Capture-Western | [40] | |||
3 | Reconstituted Complex | [56] | |||
Interacting Target Name | CDK inhibitor 1C p57Kip2 (CDKN1C) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | P57KIP2; P57(KIP2); KIP2; Cyclin-dependent kinase inhibitor p57; Cyclin-dependent kinase inhibitor 1C | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [57] | |||
2 | Reconstituted Complex | [58] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. J Biol Chem. 2005 Aug 19;280(33):29728-42. | ||||
REF 2 | Cyclin D1 represses the basic helix-loop-helix transcription factor, BETA2/NeuroD. J Biol Chem. 2002 Mar 15;277(11):8847-53. | ||||
REF 3 | Cyclin D1 associates with the TBP-associated factor TAF(II)250 to regulate Sp1-mediated transcription. Oncogene. 1999 Jan 7;18(1):239-47. | ||||
REF 4 | Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity. Oncogene. 2000 Nov 23;19(50):5703-11. | ||||
REF 5 | A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene. 2005 Jan 13;24(3):431-44. | ||||
REF 6 | Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells. Mol Cancer Ther. 2010 Jun;9(6):1596-608. | ||||
REF 7 | Cyclin D1 Is a Ligand-independent Co-repressor for Thyroid Hormone Receptors. J Biol Chem. 2002 Aug 9;277(32):28733-41. | ||||
REF 8 | Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. J Biol Chem. 2005 Apr 29;280(17):16934-41. | ||||
REF 9 | A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell. 2015 Oct 22;163(3):712-23. | ||||
REF 10 | CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms. Mol Cell Biol. 2007 Jun;27(12):4273-82. | ||||
REF 11 | Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol. 2004 Nov;24(21):9527-41. | ||||
REF 12 | Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors. J Natl Cancer Inst. 1999 Sep 15;91(18):1569-74. | ||||
REF 13 | Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. J Biol Chem. 1996 May 31;271(22):13283-91. | ||||
REF 14 | Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H. Eur J Biochem. 1996 Apr 15;237(2):460-7. | ||||
REF 15 | Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene. 1997 Mar 20;14(11):1329-40. | ||||
REF 16 | p21WAF1/CIP1 mutants deficient in inhibiting cyclin-dependent kinases (CDKs) can promote assembly of active cyclin D/CDK4(6) complexes in human tumor cells. Cancer Res. 1998 Nov 15;58(22):5053-6. | ||||
REF 17 | Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation. J Cell Biochem. 1996 Mar 1;60(3):363-78. | ||||
REF 18 | Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell. 1997 Feb;8(2):287-301. | ||||
REF 19 | The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 1996 Dec 16;15(24):7060-9. | ||||
REF 20 | Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J Biol Chem. 2003 Jul 25;278(30):27421-31. | ||||
REF 21 | Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem. 1997 May 9;272(19):12738-46. | ||||
REF 22 | Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein. Biochem Biophys Res Commun. 1999 Sep 16;263(1):35-40. | ||||
REF 23 | Role of LXCXE motif-dependent interactions in the activity of the retinoblastoma protein. Oncogene. 2001 Sep 27;20(43):6152-63. | ||||
REF 24 | Architecture of the human interactome defines protein communities and disease networks. Nature. 2017 May 25;545(7655):505-509. | ||||
REF 25 | Identification of human protein interaction domains using an ORFeome-based yeast two-hybrid fragment library. J Proteome Res. 2013 Jul 5;12(7):3181-92. | ||||
REF 26 | Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma. Nat Commun. 2017 Nov 16;8(1):1534. | ||||
REF 27 | Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1). Genes Dev. 1999 Nov 15;13(22):3027-33. | ||||
REF 28 | Calmodulin is essential for cyclin-dependent kinase 4 (Cdk4) activity and nuclear accumulation of cyclin D1-Cdk4 during G1. J Biol Chem. 1998 Dec 11;273(50):33279-86. | ||||
REF 29 | BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia. Br J Haematol. 2008 Aug;142(4):571-82. | ||||
REF 30 | A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One. 2006 Dec 27;1:e128. | ||||
REF 31 | Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 1996 Dec 2;15(23):6595-604. | ||||
REF 32 | VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 2002 Jun 1;62(11):3014-9. | ||||
REF 33 | Lysine 269 is essential for cyclin D1 ubiquitylation by the SCF(Fbx4/alphaB-crystallin) ligase and subsequent proteasome-dependent degradation. Oncogene. 2009 Dec 10;28(49):4317-25. | ||||
REF 34 | Nucleolar GTP-binding Protein-1 (NGP-1) Promotes G1 to S Phase Transition by Activating Cyclin-dependent Kinase Inhibitor p21 Cip1/Waf1. J Biol Chem. 2015 Aug 28;290(35):21536-52. | ||||
REF 35 | Tyrosine phosphorylation of the p21 cyclin-dependent kinase inhibitor facilitates the development of proneural glioma. J Biol Chem. 2012 Nov 9;287(46):38523-30. | ||||
REF 36 | Inhibition of cyclin E-cyclin-dependent kinase 2 complex formation and activity is associated with cell cycle arrest and withdrawal in oligodendrocyte progenitor cells. J Neurosci. 2001 Feb 15;21(4):1274-82. | ||||
REF 37 | Schizophrenia susceptibility gene product dysbindin-1 regulates the homeostasis of cyclin D1. Biochim Biophys Acta. 2016 Aug;1862(8):1383-91. | ||||
REF 38 | The cyclin D1-dependent kinase associates with the pre-replication complex and modulates RB.MCM7 binding. J Biol Chem. 2003 Mar 14;278(11):9754-60. | ||||
REF 39 | Self-assembling protein microarrays. Science. 2004 Jul 2;305(5680):86-90. | ||||
REF 40 | Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell. 1993 Sep;4(9):897-906. | ||||
REF 41 | Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res. 2005 Aug 1;65(15):6557-67. | ||||
REF 42 | CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997 Feb 7;88(3):405-15. | ||||
REF 43 | D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res. 1999 May 15;59(10):2297-301. | ||||
REF 44 | Yin Yang-1 inhibits vascular smooth muscle cell growth and intimal thickening by repressing p21WAF1/Cip1 transcription and p21WAF1/Cip1-Cdk4-cyclin D1 assembly. Circ Res. 2007 Jul 20;101(2):146-55. | ||||
REF 45 | Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res. 2005 Jan 15;65(2):587-95. | ||||
REF 46 | Analysis of wild-type and mutant p21WAF-1 gene activities. Mol Cell Biol. 1996 Apr;16(4):1786-93. | ||||
REF 47 | Cyclin-binding motifs are essential for the function of p21CIP1. Mol Cell Biol. 1996 Sep;16(9):4673-82. | ||||
REF 48 | A proteome-scale map of the human interactome network. Cell. 2014 Nov 20;159(5):1212-1226. | ||||
REF 49 | Toward an understanding of the protein interaction network of the human liver. Mol Syst Biol. 2011 Oct 11;7:536. | ||||
REF 50 | Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell. 2007 Jan 26;128(2):269-80. | ||||
REF 51 | Regulated expression of cofilin and the consequent regulation of p27(kip1) are essential for G(1) phase progression. Cell Cycle. 2009 Aug;8(15):2365-74. | ||||
REF 52 | C-terminal phosphorylation controls the stability and function of p27kip1. EMBO J. 2006 Nov 1;25(21):5159-70. | ||||
REF 53 | Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell. 2006 Nov 3;24(3):355-66. | ||||
REF 54 | The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Mol Cell Biol. 2013 Nov;33(22):4422-33. | ||||
REF 55 | Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev. 1993 Aug;7(8):1572-83. | ||||
REF 56 | D-type cyclin-binding regions of proliferating cell nuclear antigen. J Biol Chem. 1994 Apr 15;269(15):11030-6. | ||||
REF 57 | Dimerization of the amino terminal domain of p57Kip2 inhibits cyclin D1-cdk4 kinase activity. Oncogene. 2000 Feb 24;19(9):1147-52. | ||||
REF 58 | Stabilization of MyoD by direct binding to p57(Kip2). J Biol Chem. 2000 Jun 23;275(25):18767-76. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.